ArticleProceedings of the National Academy of Sciences of the United States of America2006
Mucosal and systemic adjuvant activity of alphavirus replicon particles.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 96 citations in OpenAlex.
- Approaches of dengue control: vaccine strategies and future aspects.Frontiers in immunology · 2024Review
- Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens.Frontiers in immunology · 2022Article
- Application of Nanotechnology in the COVID-19 Pandemic.International journal of nanomedicine · 2021Review
- A Review on Dengue Vaccine Development.Vaccines · 2020Review
- Alphavirus-vectored hemagglutinin subunit vaccine provides partial protection against heterologous challenge in pigs.Vaccine · 2019Article
- Current Understanding of the Molecular Basis of Venezuelan Equine Encephalitis Virus Pathogenesis and Vaccine Development.Viruses · 2019Review
- Article
- An Overview of Challenges Limiting the Design of Protective Mucosal Vaccines for Finfish.Frontiers in immunology · 2015Review
- Virus-vectored influenza virus vaccines.Viruses · 2014Review
- An alphavirus-based adjuvant enhances serum and mucosal antibodies, T cells, and protective immunity to influenza virus in neonatal mice.Journal of virology · 2014Article
- Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Article
- Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.PLoS pathogens · 2013Article
- Article
- Pseudoinfectious Venezuelan equine encephalitis virus: a new means of alphavirus attenuation.Journal of virology · 2013Article
- The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon.PloS one · 2013Article
- Advanced vaccine candidates for Lassa fever.Viruses · 2012Review
- Prime-boost approaches to tuberculosis vaccine development.Expert review of vaccines · 2012Review
- Article
- A novel self-replicating chimeric lentivirus-like particle.Journal of virology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
Vaccination represents the most effective control measure in the fight against infectious diseases. Local mucosal immune responses are critical for protection from, and resolution of, infection by numerous mucosal pathogens. Antigen processing across mucosal surfaces is the natural route by which mucosal immunity is generated, as peripheral antigen delivery typically fails to induce mucosal immune responses. However, we demonstrate in this article that mucosal immune responses are evident at multiple mucosal surfaces after parenteral delivery of Venezuelan equine encephalitis virus replicon particles (VRP). Moreover, coinoculation of null VRP (not expressing any transgene) with inactivated influenza virions, or ovalbumin, resulted in a significant increase in antigen-specific systemic IgG and fecal IgA antibodies, compared with antigen alone. Pretreatment of VRP with UV light largely abrogated this adjuvant effect. These results demonstrate that alphavirus replicon particles possess intrinsic systemic and mucosal adjuvant activity and suggest that VRP RNA replication is the trigger for this activity. We feel that these observations and the continued experimentation they stimulate will ultimately define the specific components of an alternative pathway for the induction of mucosal immunity, and if the activity is evident in humans, will enable new possibilities for safe and inexpensive subunit and inactivated vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.